Trial
NCT02163915
Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of TAK-137 in Adults With Attention-Deficit/Hyperactivity Disorder.
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Takeda
Collaborators
—
Condition
Attention-Deficit/Hyperactivity Disorder
Intervention
TAK-137
Why stopped
To allow evaluation of emerging non-clinical data (see detailed description below)
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-07-11